COMPARISON OF THE EFFECTIVENESS OF ONDANSETRON IN BREAST CANCER PATIENTS AFTER CHEMOTHERAPY FAC (Fluorouracil, Doxorubicin Cyclophosphamide) AND TC (Taxane Cyclophosphamide)

Azka Akhmad Fauzi; Titin Setyowati; Yanuarita Tursinawati; Muslimah

Authors

Azka Akhmad Fauzi Universitas Muhammadiyah Semarang
Titin Setyowati Universitas Muhammadiyah Semarang
Yanuarita Tursinawati Universitas Muhammadiyah Semarang
Muslimah Universitas Muhammadiyah Semarang

Keywords:

Breast Cancer, Chemotherapy, Ondansetron, FAC Regimen, T Regimen

Abstract

Breast cancer is one of the leading causes of morbidity and mortality in women worldwide. Chemotherapy with the regimens of FAC (Fluorouracil, Doxorubicin, Cyclophosphamide) and TC (Taxane Cyclophosphamide) is often used in the treatment of breast cancer, but side effects such as Chemotherapy-Induced Nausea and Vomiting (CINV) can impact the patient's quality of life. Ondansetron, a 5-HT3 serotonin receptor antagonist, has been widely used as an antiemetic therapy. This study aims to compare the effectiveness of Ondansetron in overcoming CINV in breast cancer patients receiving FAC and TC regimen chemotherapy. The research design used Quasi-Experimental with Two Group Pretest-Posttest, involving 36 patients selected by purposive sampling at Ken Saras Hospital in December 2024 – January 2025. Data were collected using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) and analyzed by paired-sample t-test and independent-sample t-test. The results showed that Ondansetron effectively lowered the RINVR score significantly in both groups (p = 0.00). However, there was no significant difference in the effectiveness of Ondansetron between the FAC and TC regimens, either before (p = 0.065) or after (p = 0.118) chemotherapy. The conclusions of this study showed that Ondansetron had good effectiveness in reducing CINV in both groups of patients, although there was no significant difference between the regimens.

Downloads

Download data is not yet available.

References

Apriantoro, N. H., & Kartika, Y. (2023). Teknik Radioterapi Kanker Payudara Post Mastektomi dengan Teknik Intensity Modulated Radiation Therapy. Indonesian Journal for Health Sciences, 7(1), 22–28. https://doi.org/10.24269/ijhs.v7i1.5178

Foundation, N. (2022). NCCN Guidelines for Patient: Nausea and Vomiting.

Ghosh, S., & Dey, S. (2010). Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting. International Journal of Collaborative Research on Internal Medicine & Public Health, 2(5), 142.

Haryani, S. (2022). Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara di RSUP Fatmawati Periode Februari 2021. 1, 50–60.

Herawati, A., Rijal, S., Arsal, A. S. F., Purnamasari, R., & Abdi, D. A. (2021). Karakteristik Kanker Payudara. FAKUMI MEDICAL JOURNAL: Jurnal Mahasiswa Kedokteran, 1(1), 44–53. https://doi.org/10.33096/fmj.v1i1.8

Herrstedt, J., Clark-Snow, R., Ruhlmann, C. H., Jordan, K., & Scotté, F. (2024). MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update. Supportive Care in Cancer, 32(1), 1–4. https://doi.org/10.1007/s00520-023-08219-y

Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., Eng, C., Feyer, P. C., Jordan, K., Noonan, K., Sparacio, D., & Lyman, G. H. (2020). Antiemetics: ASCO guideline update. Journal of Clinical Oncology, 38(24), 2782–2797. https://doi.org/10.1200/JCO.20.01296

Huang, X., Li, X., Li, J., Luo, L., Chen, H., Tan, Y., Wei, T., & Li, X. (2021). Chemotherapy ‑ Induced Nausea and Vomiting in Breast Cancer Patients : A Multicenter Prospective Observational Study. https://doi.org/10.4103/apjon.apjon-2120

Ng, W. L., & Della-Fiorentina, S. A. (2010). The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. European Journal of Cancer Care, 19(3), 403–407. https://doi.org/10.1111/j.1365-2354.2009.01068.x

Padoli, D. F., & DA, N. (2018). Penerimaan Diri dan Efek Samping Kemoterapi pada Klien Kanker Payudara yang Menjalani Kemoterapi di Rumah Sakit Onkologi Surabaya. Jurnal Keperawatan, 11(1), 24–34.

Prayoga, A. A. (2019). Manajemen Kanker Payudara Komprehensif. Airlangga University Press.

Sardjan, M. (2022). Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. 1(2), 80–85.

Sun, L., Ma, J., Zhou, Y., Ying, X., Liang, G., Pi, G., Li, Y., Luo, Y., Bi, J., He, H., & Peng, Y. (2025). Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting. BMC Cancer, 25(1), 16. https://doi.org/10.1186/s12885-024-13406-z

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 71(3), 209–249. https://doi.org/10.3322/caac.21660

Vonny, V., Putri, F., Isnawati, N., Setyaningrum, L., & Anggitasari, W. (2023). Study On the Use of Antiemetic Drugs in Breast Cancer Patients Undergoing Chemotherapy. 1(1), 47–52.